ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

ClinicalTrials.gov ID: NCT07033481

Public ClinicalTrials.gov record NCT07033481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

Study identification

NCT ID
NCT07033481
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
EIP Pharma Inc
Industry
Enrollment
20 participants

Conditions and interventions

Interventions

  • Neflamapimod Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 1, 2025
Primary completion
Aug 31, 2026
Completion
Sep 30, 2026
Last update posted
Apr 21, 2026

2025 – 2026

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Northwestern Memorial Hospital Chicago Illinois 60611 Active, not recruiting
Mayo Clinic Rochester Minnesota 55905 Active, not recruiting
Columbia University New York New York 10032 Active, not recruiting
The Ohio State University Columbus Ohio 43221 Active, not recruiting
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104 Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07033481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07033481 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →